Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.